July 14th 2025
Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any sound might reveal vulnerability. When forced to rethink the direction of life and navigate the various treatment options available while bearing the emotional toll of the unknown, it would be understandable to feel overwhelmed. Knowing there’s a clear next step can offer hope, a reason to speak up, and a renewed sense of control. For many, that step could be Pluvicto® (lutetium Lu 177 vipivotide tetraxetan).
April 4th 2025
March 18th 2025
Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
By Beth Faiman, PhD
February 27th 2025
February 26th 2025
February 18th 2025
Sponsored by Regeneron
January 8th 2025
November 21st 2024
November 12th 2024
By Sponsored by Genelux Corporation
Should I Quit My Day Job While Living With Cancer?
How Q-TWiST Can Guide Kidney Cancer Treatment Choices
Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes
Zusduri Shows Durable Responses in Some Bladder Cancers